Abstract Background & Aims Oral antiviral therapy may reduce the disease progression of
chronic hepatitis B (CHB) patients. We aimed to further investigate the efficacy of long‐term …

To investigate the incidence and risk factors of hepatitis B virus (HBV) reactivation in HBV
surface antigen (HBsAg)−/HBV core antibody (HBcAb)+ patients who underwent rituximab …

Background & Aims There have been reports of reactivation of hepatitis B virus (HBV)
infection during treatment of hepatitis C virus (HCV) infection with direct-acting antiviral …

OBJECTIVES: This study aims to assess whether quantitative HBsAg can predict durability
of chronic hepatitis B (CHB) patients stopping entecavir (ETV) treatment. METHODS: We …

Abstract Background and Aim To investigate the risk of hepatitis B virus reactivation in
patients undergoing long-term tocilizumab therapy for rheumatoid arthritis. Method From …

Background & Aims Diabetes mellitus (DM) is known to increase the risk of hepatocellular
carcinoma (HCC) among individuals with chronic hepatitis C (CHC). We aimed to evaluate …

Background/aims Direct‐acting antivirals (DAAs) are highly effective in treating chronic
hepatitis C virus (HCV)‐infected patients. The real‐world treatment outcome in Taiwanese …

Background & Aims Sofosbuvir is approved for chronic hepatitis C (CHC) patients with
severe chronic kidney disease (CKD). The impact of sofosbuvir-based therapy on renal …

Background Rheumatoid arthritis (RA) patients seropositive for hepatitis B core antibody
(HBcAb) and negative for hepatitis B surface antigen (HBsAg) are at risk of hepatitis B virus …

Background Cirrhotic patients with ascites are prone to develop various infectious diseases.
This study aimed to evaluate the occurrence and effect of major infectious diseases on the …